103 related articles for article (PubMed ID: 32564377)
1. Correlation of novel ALK
Shah KK; Neff JL; Erickson LA; Jackson RA; Jenkins SM; Mansfield AS; Moser JC; Harris AL; Copland JA; Halling KC; Flotte TJ
Histopathology; 2020 Oct; 77(4):601-610. PubMed ID: 32564377
[TBL] [Abstract][Full Text] [Related]
2. The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors.
Ronchi A; Montella M; Cozzolino I; Argenziano G; Moscarella E; Piccolo V; Iovino F; Troiani T; Alfano R; Errico ME; D'Onofrio V; Berretta M; Franco R; Zito Marino F
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3829-3838. PubMed ID: 32329859
[TBL] [Abstract][Full Text] [Related]
3. ALK Inhibitor Response in Melanomas Expressing
Couts KL; Bemis J; Turner JA; Bagby SM; Murphy D; Christiansen J; Hintzsche JD; Le A; Pitts TM; Wells K; Applegate A; Amato C; Multani P; Chow-Maneval E; Tentler JJ; Shellman YG; Rioth MJ; Tan AC; Gonzalez R; Medina T; Doebele RC; Robinson WA
Mol Cancer Ther; 2018 Jan; 17(1):222-231. PubMed ID: 29054983
[TBL] [Abstract][Full Text] [Related]
4. ALK
Xu BS; Chen HY; Que Y; Xiao W; Zeng MS; Zhang X
Oncogene; 2020 Jan; 39(1):151-163. PubMed ID: 31462708
[TBL] [Abstract][Full Text] [Related]
5. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.
Wiesner T; Lee W; Obenauf AC; Ran L; Murali R; Zhang QF; Wong EW; Hu W; Scott SN; Shah RH; Landa I; Button J; Lailler N; Sboner A; Gao D; Murphy DA; Cao Z; Shukla S; Hollmann TJ; Wang L; Borsu L; Merghoub T; Schwartz GK; Postow MA; Ariyan CE; Fagin JA; Zheng D; Ladanyi M; Busam KJ; Berger MF; Chen Y; Chi P
Nature; 2015 Oct; 526(7573):453-7. PubMed ID: 26444240
[TBL] [Abstract][Full Text] [Related]
6. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
[TBL] [Abstract][Full Text] [Related]
7. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
Thunnissen E; Lissenberg-Witte BI; van den Heuvel MM; Monkhorst K; Skov BG; Sørensen JB; Mellemgaard A; Dingemans AMC; Speel EJM; de Langen AJ; Hashemi SMS; Bahce I; van der Drift MA; Looijen-Salamon MG; Gosney J; Postmus PE; Samii SMS; Duplaquet F; Weynand B; Durando X; Penault-Llorca F; Finn S; Grady AO; Oz B; Akyurek N; Buettner R; Wolf J; Bubendorf L; Duin S; Marondel I; Heukamp LC; Timens W; Schuuring EMD; Pauwels P; Smit EF
Lung Cancer; 2019 Dec; 138():13-18. PubMed ID: 31630043
[TBL] [Abstract][Full Text] [Related]
8. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
Kim EK; Kim S
Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
[TBL] [Abstract][Full Text] [Related]
9. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
[TBL] [Abstract][Full Text] [Related]
10. Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.
Busam KJ; Vilain RE; Lum T; Busam JA; Hollmann TJ; Saw RP; Coit DC; Scolyer RA; Wiesner T
Am J Surg Pathol; 2016 Jun; 40(6):786-95. PubMed ID: 26872010
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
12. Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma.
Melchers RC; Willemze R; van de Loo M; van Doorn R; Jansen PM; Cleven AHG; Solleveld N; Bekkenk MW; van Kester MS; Diercks GFH; Vermeer MH; Quint KD
Am J Surg Pathol; 2020 Jun; 44(6):776-781. PubMed ID: 32412717
[TBL] [Abstract][Full Text] [Related]
13. The Truncated Isoform of the Receptor Tyrosine Kinase ALK Generated by Alternative Transcription Initiation (ALK
Takakura Y; Yamaguchi N; Honda T; Morii M; Yuki R; Nakayama Y; Yamaguchi N
Biol Pharm Bull; 2017; 40(11):1968-1975. PubMed ID: 29093346
[TBL] [Abstract][Full Text] [Related]
14. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
[TBL] [Abstract][Full Text] [Related]
15. Detection of Anaplastic Lymphoma Kinase Gene Re-Arrangement in Non-Small Cell Lung Carcinoma in the Indian Population: Comparison of Techniques and Immunohistochemistry Clones.
Shukla S; Pandey RK; Kant S; Garg R; Anand N; Kushwaha R; Malhotra KP; Srivastava A; Bhatt M; Husain N
Turk Patoloji Derg; 2019; 35(1):36-45. PubMed ID: 30596395
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of immunohistochemistry and fluorescent
Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident.
Arndt A; Steinestel K; Rump A; Sroya M; Bogdanova T; Kovgan L; Port M; Abend M; Eder S
J Pathol Clin Res; 2018 Jul; 4(3):175-183. PubMed ID: 29633575
[TBL] [Abstract][Full Text] [Related]
18. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).
Takeuchi K; Togashi Y; Kamihara Y; Fukuyama T; Yoshioka H; Inoue A; Katsuki H; Kiura K; Nakagawa K; Seto T; Maemondo M; Hida T; Harada M; Ohe Y; Nogami N; Yamamoto N; Nishio M; Tamura T
Ann Oncol; 2016 Jan; 27(1):185-92. PubMed ID: 26487585
[TBL] [Abstract][Full Text] [Related]
19. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
[TBL] [Abstract][Full Text] [Related]
20. ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing.
Kheng YC; Walsh K; Williams L; Wallace WA; Harrison DJ; Oniscu A
J R Coll Physicians Edinb; 2018 Mar; 48(1):20-24. PubMed ID: 29741520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]